Access the full text.
Sign up today, get DeepDyve free for 14 days.
Xing-quan Zhang, M. Sorensen, M. Fung, R. Schooley (2006)Synergistic In Vitro Antiretroviral Activity of a Humanized Monoclonal Anti-CD4 Antibody (TNX-355) and Enfuvirtide (T-20)
Antimicrobial Agents and Chemotherapy, 50
(2010)Phase 2 a study of the CCR 5 monoclonal antibody PRO 140 administered intravenously to HIV - infected adults
J. Toma, S. Weinheimer, E. Stawiski, J. Whitcomb, S. Lewis, C. Petropoulos, Wei Huang (2011)Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab
Journal of Virology, 85
W. Olson, G. Rabut, K. Nagashima, D. Tran, Deborah Anselma, S. Monard, J. Segal, Daniah Thompson, F. Kajumo, Yong Guo, John Moore, P. Maddon, T. Dragic (1999)Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5
Journal of Virology, 73
(2014)Rational design and characterization of the novel , broad and potent bispecific HIV - 1 neutralizing antibody iMabm 36
D. Kuritzkes, J. Jacobson, W. Powderly, E. Godofsky, E. Dejesus, F. Haas, K. Reimann, J. Larson, P. Yarbough, V. Curt, W. Shanahan (2004)Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.
The Journal of infectious diseases, 189 2
A. Trkola, T. Ketas, K. Nagashima, Lu Zhao, T. Cilliers, L. Morris, John Moore, P. Maddon, W. Olson (2001)Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140
Journal of Virology, 75
(2013)Anti - CD 4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV - 1 , with natural resistance mediated by the loss of a V 5 glycan in envelope
C. Pace, R. Song, C. Ochsenbauer, C. Andrews, D. Franco, Jian Yu, D. Oren, M. Seaman, D. Ho (2013)Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1
Proceedings of the National Academy of Sciences, 110
A detailed understanding of the breadth and potency of iMab and naturally occurring resistance
Ming Sun, C. Pace, X. Yao, Faye Yu, Neal Padte, Yaoxing Huang, M. Seaman, Qihan Li, D. Ho (2014)Rational Design and Characterization of the Novel, Broad and Potent Bispecific HIV-1 Neutralizing Antibody iMabm36
JAIDS Journal of Acquired Immune Deficiency Syndromes, 66
R. Song, D. Oren, D. Franco, M. Seaman, D. Ho (2013)Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity
Nature biotechnology, 31
W. Spreen, D. Margolis, J. Pottage (2013)Long-acting injectable antiretrovirals for HIV treatment and prevention
Current Opinion in HIV and AIDS, 8
S. Burastero, B. Frigerio, L. Lopalco, F. Sironi, D. Breda, R. Longhi, G. Scarlatti, S. Canevari, M. Figini, P. Lusso (2011)Broad-Spectrum Inhibition of HIV-1 by a Monoclonal Antibody Directed against a gp120-Induced Epitope of CD4
PLoS ONE, 6
(2011)Safety, efficacy, and pharmacokinetics of ibalizumab in treatment-experienced HIV-1 infected patients: a Phase 2b study. 51st Interscience Conference on
Michael Freeman, M. Seaman, Sophia Rits-Volloch, X. Hong, Chia-Ying Kao, D. Ho, Bing Chen (2010)Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody.
Structure, 18 12
P. Kwong, J. Mascola, G. Nabel (2013)Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Nature Reviews Immunology, 13
(2014)Abstract SY 12.02. Recent symposium presentation detailing the progress in the design of native IgGlike bispecific antibodies including the very broad and potent PRO 140/10E8 bispecific
L. Walker, S. Phogat, P. Chan-Hui, D. Wagner, P. Phung, J. Goss, T. Wrin, M. Simek, S. Fling, J. Mitcham, J. Lehrman, F. Priddy, O. Olsen, S. Frey, P. Hammond, S. Kaminsky, T. Zamb, M. Moyle, W. Koff, P. Poignard, D. Burton (2009)Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Safety , efficacy , and pharmacokinetics of ibalizumab in treatment - experienced HIV - 1 infected patients : a Phase 2 b study
(2010)of HIV - 1 primary receptor CD 4 in complex with a potent antiviral antibody
J. Jacobson, J. Lalezari, M. Thompson, C. Fichtenbaum, M. Saag, B. Zingman, P. D'Ambrosio, N. Stambler, Y. Rotshteyn, A. Marozsan, P. Maddon, S. Morris, W. Olson (2010)Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults
Antimicrobial Agents and Chemotherapy, 54
(2014)Subcutaneous ibalizumab in at-risk healthy subjects. 54th Interscience Conference on
K. Reimann, Wenyu Lin, Sarah Bixler, Beth Browning, Barbara Ehrenfels, J. Lucci, Konrad Miatkowski, Dian Olson, Thomas Parish, Margaret Rosa, Frederick Oleson, Yen Hsu, Eduardo Padlan, N. Letvin, L. Burkly (1997)A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties.
AIDS research and human retroviruses, 13 11
Most recent clinical trial of subcutaneous iMab with detailed PK/PD findings, important also for identifying delay in response to HAV immunization
C. Pace, M. Fordyce, D. Franco, Chia-Ying Kao, M. Seaman, D. Ho (2013)Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope
JAIDS Journal of Acquired Immune Deficiency Syndromes, 62
J. Jacobson, D. Kuritzkes, E. Godofsky, E. Dejesus, Jeffrey Larson, S. Weinheimer, S. Lewis (2008)Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults
Antimicrobial Agents and Chemotherapy, 53
J. Jacobson, M. Thompson, J. Lalezari, M. Saag, B. Zingman, P. D'Ambrosio, N. Stambler, Y. Rotshteyn, A. Marozsan, P. Maddon, S. Morris, W. Olson (2010)Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.
The Journal of infectious diseases, 201 10
L. Burkly, D. Olson, R. Shapiro, G. Winkler, J. Rosa, David Thomas, C. Williams, Patricia Chisholm (1992)Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion.
Journal of immunology, 149 5
P. Pugach, T. Ketas, E. Michael, John Moore (2008)Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.
Virology, 377 2
R. Perez-Jimenez, Álvaro Alonso-Caballero, Ronen Berkovich, D. Franco, Ming-Wei Chen, P. Richard, Carmen Badilla, Julio Fernandez (2014)Probing the Effect of Force on HIV-1 Receptor CD4
ACS Nano, 8
Next-generation bispecific antibodies containing iMab with synergistic potency and improved breadth, and likely to represent the future of antibodies in this class
J. Jacobson, M. Thompson, J. Lalezari, M. Saag, B. Zingman, P. D'Ambrosio, N. Stambler, Y. Rotshteyn, A. Marozsan, P. Maddon, S. Morris, W. Olson (2010)Anti – HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140 , a CCR 5 Monoclonal Antibody
Another bispecific antibody constructed with iMab that simultaneously targets both CD4 and CD4-induced Env sites
J. Jacobson, M. Saag, M. Thompson, M. Fischl, Ralph Liporace, R. Reichman, R. Redfield, C. Fichtenbaum, B. Zingman, Mahesh Patel, J. Murga, S. Pemrick, P. D'Ambrosio, Martin Michael, H. Kroger, Hieu Ly, Y. Rotshteyn, R. Buice, S. Morris, J. Stavola, P. Maddon, A. Kremer, W. Olson (2008)Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.
The Journal of infectious diseases, 198 9
R. Song, D. Franco, Chia-Ying Kao, Faye Yu, Yaoxing Huang, D. Ho (2010)Epitope Mapping of Ibalizumab, a Humanized Anti-CD4 Monoclonal Antibody with Anti-HIV-1 Activity in Infected Patients
Journal of Virology, 84
J. Moore, Q. Sattentau, P. Klasse, L. Burkly (1992)A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells
Journal of Virology, 66
REVIEW URRENT Monoclonal antibodies to host cellular receptors PINION for the treatment and prevention of HIV-1 infection a,b b Craig Pace and Martin Markowitz Purpose of review Clinically relevant monoclonal antibodies (mAb) to host cellular receptors have been generated to both the CD4 receptor and the CCR5 coreceptor, cell surface proteins critical for HIV-1 entry. Ibalizumab is a novel humanized mAb that binds to a conformational epitope on CD4 and blocks entry of HIV-1. It has broad and potent antiviral activity in vitro and in vivo. PRO 140 is a humanized mAb that binds to the CCR5 coreceptor and inhibits CCR5-tropic HIV-1 by interfering with viral entry. Antiviral activity has been demonstrated both in vitro against R5 viruses and in vivo in HIV-1-infected individuals harboring CCR5- tropic virus. Recent findings Both antibodies have been administered intravenously in early-phase clinical trials, and current emphasis is on the development of formulations that can be administered subcutaneously. Most recently, bispecific antibodies combining either ibalizumab or PRO 140 with anti-Env broadly neutralizing antibodies have been constructed with vastly improved in-vitro neutralizing profiles, and may offer substantial advantages in the clinic. Summary mAb to host cellular receptors particularly when combined with broadly neutralizing antibodies
Current Opinion in HIV and Aids – Wolters Kluwer Health
Published: May 1, 2015
Access the full text.
Sign up today, get DeepDyve free for 14 days.